It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older.

In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU – for ...

Bylvay was approved for progressive familial intrahepatic cholestasis (PFIC) in 2021 and for Alagille syndrome (ALGS) in 2023. In a note to clients this week, analysts with ODDO BHF said Bylvay ...

Ipsen SA reported robust financial performance for the first quarter of 2025, surpassing revenue forecasts and showcasing strong growth across its therapeutic areas. The company’s revenue ...

Apr. 17, 2025 — Three consecutive years of drought contributed to the 'Barbarian Conspiracy', a pivotal moment in the history of Roman Britain, a new study reveals. ... A New Record for ...

The findings are ... New Genetic Cause of Neurodevelopmental Disorders Apr. 10, 2025 — A seminal study has uncovered a new genetic cause of neurodevelopmental disorders (NDDs). The discovery ...

for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and... at 08:35 Riverbed Named Data Observability Solution Provider of the Year in 6th Annual Data Breakthrough ...

Data on laboratory findings, diagnoses, and outcomes were collected. Read more about GPP treatment The results revealed that, over the 11-year study period, fewer psoriasis patients were hospitalized ...